Seiji Isonishi

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

Noriyuki Katsumata, Makoto Yasuda, Fumiaki Takahashi et al. · The Lancet · 2009 · 733 citations

Medicine, Oncology, Pharmacology +12

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial

Noriyuki Katsumata, Makoto Yasuda, Seiji Isonishi et al. · The Lancet Oncology · 2013 · 481 citations

Medicine, Gynecology, Oncology +13

Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells

Aikou Okamoto, Takashi Nikaido, Kazunori Ochiai et al. · Clinical Cancer Research · 2005 · 395 citations

Medicine, Oncology, Pharmacology +15

A Novel Gene, CRR9, Which Was Up-Regulated in CDDP-Resistant Ovarian Tumor Cell Line, Was Associated with Apoptosis

Kazue Yamamoto, Aikou Okamoto, Seiji Isonishi et al. · Biochemical and Biophysical Research Communications · 2001 · 151 citations

Life Sciences, Molecular Biology, Oncology +16

Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial

Toru Sugiyama, Aikou Okamoto, Takayuki Enomoto et al. · Journal of Clinical Oncology · 2016 · 144 citations

Medicine, Gynecology, Oncology +15